SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 21st, 2007 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 19, 2007, by and between Rexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and KT&G Corporation, a Korean corporation (the "Purchaser").
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 21st, 2007 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of __________, __, 200__, by and between Rexahn Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and KT&G Corporation, a Korean corporation (the “Purchaser”).
NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR ANY STATE SECURITIES LAWS IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Warrant Agreement • November 21st, 2007 • Rexahn Pharmaceuticals, Inc. • Pharmaceutical preparations
REXAHN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), hereby certifies that, for value received, Rexgene Biotech Co., Ltd. or its registered assigns (the “Holder”), is entitled to purchase from the Company up to a total of 142,857 shares of the common stock, $0.0001 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price equal to $1.80 per share (as adjusted from time to time as provided in Section 9, the “Exercise Price”), at any time and from time to time from and after the date hereof and through and including the date that is three years from the date of issuance hereof (the “Expiration Date”, as adjusted pursuant to Section 4(a)), and subject to the following terms and conditions. This warrant (this “Warrant”) is issued pursuant to that certain Securities Purchase Agreement, dated as of November 20, 2007, by and between the Company and Rexgene Biotech Co., Ltd. (the
